Radius Announces Oral Presentation Of The ACTIVE Phase 3 Clinical Trial Of Abaloparatide-SC For Postmenopausal Women With Osteoporosis At The International Society Of Endocrinology And The Endocrine Society (ICE/ENDO 2015)
WALTHAM, Mass., Jan. 29, 2015 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq:RDUS), today announced that the Annual Meeting Steering Committee of ENDO 2015 has selected the company's recently completed Phase 3 ACTIVE study of abaloparatide-SC in post menopausal osteoporosis for the Late-Breaker oral presentations session at the International Society of Endocrinology and the Endocrine Society (ICE/ENDO 2015) in San Diego from March 5-8, 2015. A second abstract of an abaloparatide-SC study has been selected for another oral presentation, while two other abstracts for abaloparatide-SC will be presented in poster sessions. In total, Radius Health will be presenting four abstracts from the development program for abaloparatide-SC at the world's largest scientific endocrinology meeting.
"We are extremely pleased to have been given the opportunity by the Endocrine Society to present the positive findings of the Phase 3 ACTIVE study of our investigational drug abaloparatide-SC, which may have the potential to treat the many patients suffering from postmenopausal osteoporosis around the world," said Robert E. Ward, Radius President and Chief Executive Officer. "We eagerly await the results of the ongoing ACTIVExtend trial expected in the second quarter of 2015, and we are on track for the submission of an NDA to the FDA in the second half of 2015."
The details of the abstracts Radius Health will present at ENDO are detailed below:
LATE-BREAKER Title: Effects of Abaloparatide-SC on Vertebral and Non-Vertebral Fracture Incidence in Postmenopausal Women with Osteoporosis-Results of the Phase 3 ACTIVE Trial
Presenting Author: Paul D. Miller MD
Abstract Number: 22577
Oral Presentation Date/Time: Thursday, March 5, 2015
Oral Session Number:LB-OR013-New Discoveries in Bone Health and Disease
Room/Details: Room 6F, San Diego Convention Center
Title: Abaloparatide Treatment Increases Bone Formation with a Corresponding Increase in Bone Resorption Resulting in Marked Bone Gains in Osteopenic Ovariectomized Monkeys and Rats
Presenting author: Hila Bahar DMD, PhD
Abstract Number: ORO8-3
Oral Presentation Date/Time: Thursday, March 5, 2015
Oral Session Number: ORO8-Parathyroid and Bone Metabolism
Room/Details: San Diego Convention Center
Title : Twenty-Four Weeks of Treatment with Abaloparatide-SC Significantly Improves Trabecular Microarchitecture As Indirectly Assessed By Trabecular Bone Score (TBS) Conformations
Presenting author: Gary Hattersley, PhD
Poster Board Number: FRI-250
Presentation Date/Time: Friday, March 6, 2015, 1:00 – 3:00 PM
Room/Details: Expo Hall, San Diego Convention Center
Title: Improved Bone Mass and Architecture at the Femoral Neck with Abaloparatide Treatment in Monkeys and Rats
Presenting Author: Hila Bahar DMD, PhD
Poster Board Number: THR-222
Presentation Date/Time: Thursday, March 5, 2015, 1:00-3:00 PM
Room/Details: Expo Hall, San Diego Convention Center
Abstracts will be available to view on-line after February 6, 2015 at https://endo.confex.com/endo/2015endo/webprogram/authora.html
About the Investigation Drug Abaloparatide
Radius' investigational drug is a synthetic peptide analog of human parathyroid hormone-related protein (hPTHrP), a naturally occurring bone-building hormone that we believe has the potential to increase bone mineral density by stimulating new bone formation. Abaloparatide-SC is an investigational drug currently in Phase 3 development for potential use as a daily self-administered injection for the treatment of patients with postmenopausal osteoporosis at high risk of fracture. Radius is also developing abaloparatide-TD, for potential use as a short wear-time transdermal patch designed to administer abaloparatide without the need for subcutaneous injection, based on 3M's patented Microstructured Transdermal System technology.
About Radius Health
Radius Health, Inc. is a science-driven biopharmaceutical company developing novel differentiated therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases including hormone responsive cancers. The company's lead development candidate is the investigational drug abaloparatide for subcutaneous injection, currently in Phase 3 development for the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for potential use in osteoporosis and the investigational drug RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, including breast cancer brain metastases. www.radiuspharm.com.
CONTACT: Investor Relations Barbara Ryan 203-274-2825 bryan@radiuspharm.comHelp employers find you! Check out all the jobs and post your resume.